- NewsCategory：
- All Company news Industry news
common105One result
-
1011
Viela Bio Enters Strategic Collabo•↕ration with Mitsubishi Tanabe Pharma to De>§velop and Commercializeγ≠ Inebilizumab for Autoimmune ☆€λ&Diseases in Japan and Other Asia Regions
THURSDAY, OCTOBER 10, 2019Viela Bio, In¥♥×c. and Mitsubishi Tanabe Pharma Corp÷×oration (“MTPC”) toda 'y announced a collaboration focused on→∏> the development and com•<mercialization of inebilizumab – Viela’s humanize±≥±d anti-CD19 monoclona∏✔l antibody – in nine Asia regions fo•<™r neuromyelitis optica s§∏γ∏pectrum disorder (NMOSD✘↔✔α), as well as other potentia↑βl future indications.“This partnership a∑γ∞dds to our ability to commercialize inebilizuma™¥b globally, subject to regulatory approval,” ↕ commented Bing Yao, Ph.D., Viela’s Executiv∏≠₽e Chairman and Chief Executiv↕±e Officer. “As a well-establishedδ∞✔∞ pharmaceutical company in Ja ∑☆pan, Mitsubishi Tanabe has strong pro×₩←duct development and commercialization capab÷₩ilities in Asia, and we believe, is an ide•↑Ω×al partner for expandin☆♦↑>g inebilizumab’s potential ↕♦reach to thousands o∑λf additional patients in need of vi∏δ♥able treatments, with NMOS§©σ≠D as an initial indication.”Under terms of the co<αllaboration, Viela will receive an up-front lice★&®nsing fee of $30 million a$∏s well as additional payment$£s contingent on certain development and co←δ×mmercial milestones, plus payments based™¥₽↔, in part, on sales revenue. MTPC will ♥α®be responsible for leading developmσ ≈ent and commercialization of inebilizumab ©"÷in Japan, Thailand, South Korea, Indo&≠nesia, Vietnam, Malaysia, Philippines, Sin≈£α gapore, and Taiwan.“Our organization is d∞§∏elighted to partner with Viela to dev ¥elop and commercialize their promis€ ing product candidate ₽'✔inebilizumab for aut≈α♦®oimmune and inflammatory diseas€♠☆δes,” said Masayuki Mit&✘εsuka, MTPC President &a©☆mp; Representative Direct✔αor. “Inebilizumab is an exciting product candida¶'te that, based on the results from the N-MOment€σ→£um pivotal study, is well-positioned to p&∞×δrovide meaningful benefit for patients wit h NMOSD, and potentially additional di↓$$seases, subject to regulatory™♦♣ approval. We are excited to work with Viela ↑&>λto advance inebilizumab in₽®←♠ Japan and other Asia regions, an•d look forward to a productive partnershipφ¥¶ between our companies.”The U.S. Food and Drug ∑©Administration (FDA) recently accepφε→ted for review Viela’s Bio↔≤>©logics License Appli↓≥&cation (BLA) for inebilizumab for the treatmeα↓nt of NMOSD. information source:pharma >§≥focus AsiaThe original link:https:https://www.pha↓λrmafocusasia.com/news/viela-bio-enters-strategi"☆≥c-collaboration-with-mi♥λσtsubishi-tanabe-pharma-to-develλβop-and-commercialize-inebilδ>izumab-for-autoimmune-dis¶'♦Ωeases-in-japan-and-other-asia-reπ→gions2019 Asia-pacific★• pharma IP Leader Summit: http://en.zenseegrou±<'p.com/p/510934/will be held in Beijing §<" on November 14-15∞ , and will attract more than 500 industr"λ♣™y experts from domestic and foreign pharmaceΩ→ utical companies, biotechnology coφ∏mpanies, governments, associat≥≠☆★ions, law firms, intell"↕"→ectual property agents and other compani<βes to attend.Official registration a¥∏♦∞nd consultation channels:Contε¥act：AnnPhone: 021-65650305Email：Marketing@π∏♣αzenseegroup.comhttp://en.zenseegroup£γσ→.com/p/510934/ -
1010
4D Pharma collabor4D★≈ Pharma collaborates witφ✘↔h MSD to develop live biotherapeutic p ←πroducts for vaccinesates with Mβ∏SD to develop live biotherapeutic produ♦ ©cts for vaccines
4D pharma plc, a leading pharmaceutical company÷↔ in the development of live biotherapeutics, toda"<♦y announces that the company has ent±ered into a research coll★♠§♦aboration agreement and an o♣✔♣ption license to use with MSD (tradi>↓ng name of Merck & Coδ<., Inc., in Kenilworth , New Jersey , Unite"<•d States of America) to Discover and Develop L¥← ←ive Biotherapeutic Productsδ× ("LBP") for vaccines.Under the÷>®© terms of the agreement, MicroRx®, the propr§←αietary platform of 4D, will be as ₽φsociated with MSD's expertise in the development •↑↕™and commercialization of new vaccines, in >¶↓↕order to discover and deve→δλlop LPBs as vaccines in maximum three unλβ♣disclosed indications. 4D has the right♦™★±, subject to certain conditions, t₹™ o purchase from MSD for $ 5 mil×<™lion common shares of 4D during the first ®β12 months of the col×® λlaboration. In addition to an initial cash paymen↓☆∑↑t, for each indication,¶ 4D will be eligible to receive up to $ € 347.5 million in exercise of options≥≈σγ and regulatory and devel↔☆₹↔opment milestone payα÷✘✔ments, as well as royal≤σ×ties the annual net sales of any lic→ensed product resulting from the collabora•>λtion.Duncan Peyton , CEO of 4D, s§☆←aid, "This collaborative researcλ h agreement brings together 4D's innovations in t•♣®"he microbiome field and MSD's traδα©✔ck record in the development of advanced v€♥♠≥accines. MSD and 4D wor♥ δ¥ked closely together combining world-class sci≥∞∞entific knowledge to develop'↔$ a work plan to advance understanding of this£←• field, with the goal of generating ♥γ≠♣a new class of vaccines in areas where unmet ne↔π♠↔eds are important. "Daria Hazuda , Scientific ★ λ Director of MSD's Exploratory Science Center ∞≥and Vice President of Research on MSD's Infect÷ ious Diseases and Va±☆ccines Discovery, said, "A key element of our €¥∞goal at the Center fo×r Exploratory Science is the asΩΩδ→sessment of emerging areas of emerging§δ© biology that are lik≥≥ely to have a major beneficial impact ♣γon human health. By applyin♠αg MicroRx® technology of 4D,☆€€≥ we hope to obtain useful infor €♦×mation on the role of ↔§→Ωthe host microbiome in modulating the i×¥✔↔mmune response and, ulβ≥©timately, the protection ×conferred by vaccines. "information&nσbsp;source:pharma focus Asiaε✘The original link:https:https://www.pharmafocu ©±☆sasia.com/news/4d-pharma-collab™₩∑'orates-with-msd-to-develop-Ω ≥live-biotherapeutic-products-for-vaccines201ε♣§♣9 Asia-pacific pharma IP Leader Summit: http://en®≥$$.zenseegroup.com/p/510934/will be hel©∞÷d in Beijing &♦£λnbsp;on November 14™λ-15, and will attract more than 5&↓00 industry experts from domestic andγ foreign pharmaceutical companies, biotechnolog☆∏y companies, governments, a←πssociations, law firms, intellectual propertπσ♠y agents and other companies to attend.Official r×αλegistration and consulta↕≈tion channels:Contact：AnnPhone: 021-65650305≈↑σEmail：Marketing@zenseegroup.comhtγtp://en.zenseegroup.com/p/510934/ -
1009
Goldfinch Bio Announces Licensing∏ ✘ Agreement with Takeda for CB1 Monoclonal A€ε$♥ntibody for the Treatment of Rare a ∑nd Metabolic Kidney Diseases
Goldfinch Bio, a U.S.-based, clinical stage → biotechnology companyδ÷ focused on discovering and developing prec∑δ≥ision medicines for the treatment of kidney diseaφ★ses, today announced it£₩> entered into a license agreem≤₹& ent with Takeda Pharmaceutical Compα♣any Limited (“Takeda”) for worldwid ★e rights to a preclinical, peripherally-rest¥±±ricted cannabinoid receptor 1 (CB1) monoclonal anε&λtibody. Goldfinch Bio will assume all development≥>± and commercialization re §✔sponsibilities for the treatment of rare and mφδ etabolic kidney diseases woΩπrldwide. However, th☆±×e agreement grants Takeda the option, prior♠₩ to the initiation of pivotal stββ₩udies, to request Go≠♣εldfinch Bio negotiate ©<with Takeda for sub-licensing of Japanese rights≤↕ γ to Takeda. Financial terms of the δ↕agreement were not disclosed. GoldfincΩ↔<h Bio plans to file an investigatβ¶Ωional new drug (IND) application ≈ε§∏for this CB1 inhibito↑ ✘≠r, re-named GFB-024, in the second ha÷γlf of 2020.“In recent years, our unders↕≈♥™tanding of the role of CB1 si✔®gnaling in exacerbating progressive ki↑£δdney diseases has grown substantially. In t'♠his context, a monoclonal antibody direct₹$¶πed toward the CB1 receptor is potentialβ™ly well-suited to elicit the benβ§σeficial pharmacology associated with ✔$₽the peripheral inhibition of th>♦$e CB1 receptor,” said Anthony §α∞•Johnson, M.D., President and Chief ↔≤Executive Officer of Goldfinch ¶≠σBio. “Goldfinch Bio will deployσ •★ its biology platform an¶™§d Kidney Genome AtlasTM to develop this th$'€erapeutic agent in subsets of≈↓∏ patients with kidney diseases m >α÷ost likely to preferentially $αrespond to CB1 inhibition. With GFB-887, our &¶ TRPC5 inhibitor for FSGS, in Phase 1 clinic₩ al development, this periphe∑₩±♦ral CB1 inhibitor will be the second clin•>÷ic-ready program in Goldfinch Bio’s pipe¶λline. We look forward to coll♥§aborating with Takeda on t ♠πhis program.”“Goldfinch Bio is id♠$★®eally suited to advance development ©"£←of this program,” said Dan Curran, M.D., SVP λ>and Head, Rare Disea™¶Ω>ses Therapeutic Area Unit, Takeda. “The Ω§ application of its precision medicine appro ∞'<ach, from candidate target validation thro≤>₩↕ugh to identification β∑™of potential treatment-relevant subgroups, i×δs unique in the developme λnt of chronic metaboli♣₩≤c kidney disease treat♥δments.”Preclinical data support the inhibi≈∑©tion of CB1 signaling as a nov♦→el treatment of Diabetic ↔™Nephropathy (DN) and obesity-rela→<₩ted glomerulopathies (ORG), giv✘&εen the potential metabolic benefits and direct efπ∑fects on the kidney to prev→©ent fibrosis and preserve kidney function.↕↑≈→ DN develops in 30 to 40 perce★©∏nt of patients who have diabetes and i™φs a leading cause of morbidity, mortality and e★"↔∏nd-stage kidney disease✘γ€€ in the United States and wo<÷$∞rldwide. ORG is a rare kidney disorder character¶λ✘®ized by significant proteinuria ♦βand progressive renal dysfunction. Although §☆®both DN and ORG are increasing in prevalence in ≈↑ parallel with the obesity epidemic, well-establi→®πshed disease modifying therapies are lacking. "Goldfinch Bio plans to initiate a pha→"©se 1 study for GFB-024 in §Ωλ↑2H 2020.information source:pharma₽"÷ focus AsiaThe original link:https:// €¶www.pharmafocusasia.com/news/goldfi"←×nch-bio-announces-lic♦♠§♦ensing-agreement-with-takeda-for•§©φ-cb1-monoclonal-antibody-for-the-treatment-of-≠↑rare-and-metabolic-kidney-diseases2019 Asia-p€☆ acific pharma IP Leadλ"er Summit: http://en.zenseegroup.com/p/40¥λ 4716/ will be held in B♠↑•eijing on November 14-15, and ≈↑ ∑will attract more than 500 industry experts fr≈∞om domestic and foreign pharm↔✘aceutical companies,≥' biotechnology compaα§'nies, governments, associat≈₩♠→ions, law firms, intellec↓$ε♦tual property agents anβ↑§<d other companies to attend.Official registδ↔ration and consultation channels:Contact：Anεδ nPhone: 021-65650305Ema→≥•αil：Marketing@zenseegroup.comhttp '≠://en.zenseegroup.com/p/510934/£¥₩¥ -
1008
Prometheus Biosciences, Inc., π×✔Enters Into Multi-Target Strategic Col☆€∏ laboration with Taked•₽'a to Develop Targeted Tλ←herapies for Inflammatory Bo¥≈∑↓wel Disease
Prometheus Biosciences, Inc., a biopharmaceutic₩±€al company committed to the discovery, dev↓$₽elopment, and commercialization of a broadε'ε portfolio of novel ✔ precision therapeutics and compan £ion diagnostics for patients living γ↑ with unmet needs in gastroen ♦♦"terology and autoimmune diseases, announced thatεβ it has entered into a global, multi-target sεεαtrategic collaboration with Takeda Pharmaceuti≈→∑cal Company Limited (Takeda) to diλ±×scover, develop, and commercialize no★✔vel therapies for inflammatory bowel diseaseε± (IBD). The collabor∞★ation combines the proprietary bioinforma÷tics discovery platform and c±↕ompanion diagnostic tools developed©↔• by Prometheus Biosciences↑σ with Takeda's expertise in g∞∞÷astroenterology and drug development, in or✘✘φder to discover and δ•γadvance up to three targeted IBD therapeutics andλ÷ companion diagnostics. ε Promethe'→σ us Biosciences will be responsible for γπ the identification and β ₹validation of three u₽•₽nique drug targets for IBD, al£¥↕™ong with the development and comm≥←©ercialization of companion diagnostics ε₩§to complement the targeted drugs. Tak >≥eda will be responsible for all drug←→€≥ discovery, clinical dΩφevelopment, and commercialization act₽$ivities for the resulting targeted≤¥ therapeutics."We are impre®≈πssed with Takeda's commitment to developing a po ÷↔¶rtfolio of therapies to π address all IBD patients, espec'λ★×ially those with unmet needs," sai >♣£d Mark McKenna, chief ®•γ↕executive officer, Pro♣Ωmetheus Biosciences.&nb₹↕✔∏sp; "We believe that a ta÷±→®rgeted, precision medicine approach is needed ±γ±γto deliver new, effective therapeutic optioΩ÷Ω∏ns in inflammatory bowel disease. Through o£≠±ur partnership, we are excited to≥ combine the Prometheus bioinformati₩ cs platform and advanced machine lear∏∑∏≤ning techniques with Takeda's expertise in&₹γ♦ drug development to delive≠®r a new generation of IBD therapies."Under the te♣λ★rms of the agreement, Prometheus Bi↕ osciences will recei'φ€ve an undisclosed initi€ al upfront payment from ✘€Takeda and is eligible to receive up to $420M€♦γ± in development, regulato>§≥♥ry, and commercial milestone€"↕ payments, in total, across all three programs∑¶. In addition, Prometheus Biosciences i↔s eligible to receive royalty paymen"•←ts on global commercial sales from each progrε↑♠©am.information sourc♠σe:pharma focus AsiaThe original link:https:h<αλttps://www.pharmafocusaβ✔© sia.com/news/prometheus-biosci$¶•↕ences-inc-enters-into-multi-target-strat•ε™∏egic-collaboration-with-takeda-toφ -develop-targeted-therapies-for-inflamm ✔×atory-bowel-disease2019 Asia-pacific pharma IP Lγ∑↑eader Summit: http://en.zenseegr§↔♠ oup.com/p/510934/ ≈γ×;will be held in Beijing ₩≤≈δ; on Novemb&∏₽♣er 14-15, and will attract more than 500 indust"↑ry experts from domestic a₩×∏∏nd foreign pharmaceutical companies,λ∏ biotechnology companies, governmen♠≈>λts, associations, law ★Ω£firms, intellectual property agents and other co÷<mpanies to attend.Official registrat&☆ion and consultation chann✔∑✔els:Contact：AnnPhone: 021-65650305Email✔：Marketing@zenseegroup.comhttp://en.zenseegrou™βp.com/p/510934/ -
0929
Catabasis Pharmaceuticals and the Jain Foun∞→Ωdation Announce a Preclin¶λical Research Collaboration to Study Edasalon ♦∞<exent in Dysferlinopathy
Catabasis Pharmaceuticals, £"♣£Inc., a clinical-stage biopharmaceutic↕σ✘al company, and the Jain Founβ↑<♠dation, a non-profit founda"≠tion whose mission is to cure m>₽uscular dystrophies caused by dysferlin p<✔✘rotein deficiency, announced ↕ΩΩ∞a preclinical research co₩✔llaboration to study edas>β÷alonexent (CAT-1004) δin Dysferlinopathy. Dysferlinopathy (Limb-♥<girdle muscular dystrophy type 2B / Miyoshi my$↓ ∏opathy) is a serious rare disease thatπ≤∑ causes progressive muscle weakne✔λss for which there are currently n♣Ω•$o approved treatment options. Edaε↕salonexent is in Phase 3 deπ®↑≥velopment for the tr↔♥< eatment of Duchenne muscular dystropπhy (DMD) and has the potential to benefi≤βt patients with other disea ±ses, such as Dysferlinopathy.In Dys±πα₽ferlinopathy, muscles lack dysferlin and as ♥♦✔a result NF-kB is chronically activated. Eda•♦≥salonexent, an oral small molecule de✘δ signed to inhibit NF-kB, h>★↓€as the potential to slow disease p±λrogression in dysferlin-deficient poσ™γpulations. Under this collaboration, ♣∑Catabasis and the Jain Fou∑>♠÷ndation are conducting a pre≥•↔™clinical study to evaluate th"✔₹e potential of edasalonexent as a therapeutic '$intervention for Dysferlinopathy by €₽ measuring disease progression in dys♣ferlin-deficient mice treated with €≥∞edasalonexent. The study will utilize m®±₹₹agnetic resonance imaging (MRI) and magnetic resδ↓ βonance spectroscopy (MRS) to measure musclΩ •✘e volume, fat accumulation, and ot <φ←her changes in the dy✘ ¶sferlin-deficient mice. Initial results ar§≈↑&e expected in the first half↕↕¥ of 2020.“We look forward to working w∞®απith Catabasis to advance rδ€≈esearch for Dysferlinopathy,” said Laura Rufi£→<bach, Ph.D., and Doug Albrecht, Ph.↕≈↕D., Co-Presidents of the Jain Foundatio☆ ∏n. “Patients with DysferlinΩ☆opathy (LGMD2B / Miyoshi myopathy) experiλ∑ence a progressive and debilitating ≈decline in muscle function whi↔✔÷φch significantly impacts th≥§eir lives. As there ε"♦ are currently no treatment options, we •↑Ω™are excited to explore the potential≥φ of edasalonexent to benefit those liv'<ing with this disease.”“The chronic activatiγ&>on of NF-kB is a key driver in many neuromusπ•ε↔cular disorders, includ® ing Duchenne muscular dystrophy. Evidence of N↓ F-kB activation in Dysferlinopathy su∏©↓↓ggests a similar disease m↔¥echanism and opportunity for interventi♣"on. In the MoveDMD trial and open-↓ εlabel extension, tre₹φatment with edasalonexent slowed disease pro♣β'gression compared to the off-trea↓↕♠'tment control period. Through this collaboration, we looσ≠¶k forward to learning more about ≥β"the potential of edasalonexent in Dy≥↓₹↑sferlinopathy, where'ε, similar to Duchenne, there is also a s☆§✘φignificant unmet need,” said Andrew Nicho✔∑₹ls, Ph.D., Chief Scient™₽ ific Officer at Catabasis Pharmaceuticals₹.information source:pharma focus AsiaThe↓≤ original link:https:https://www.pharmaf♦$ocusasia.com/news/catabasis-p>harmaceuticals-and-the-jain-found₽±↕ation-announce-a-preclinical-researchδ∑-collaboration-to-study-eda≠¶↓§salonexent-in-dysferlinopathy2019 A×$♦↕sia-pacific pharma IP Leader Summit±→ : http://en.zenseegroup.com/p/404716↓♦σ/ will be held in Beσβ♥≈ijing on&nbs→α←₽p;November 14-15, and wi<¶×ll attract more than 500 indusγ¥♠try experts from domestic and foreign phar¶"₹εmaceutical companies,& π biotechnology companies, governments, associatiπ♦ons, law firms, intellectual property agents and'' other companies to attend.Official registra<®tion and consultation chann₹els:Contact：AnnPhone: 021-656©&50305Email：Marketing"δπ×@zenseegroup.comhttp://en.zenseegroup.com∏ε/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016